WO2001032197A3 - Methodes d'utilisation de lp8, une proteine liee au pdgf, afin de traiter les troubles musculosquelettiques - Google Patents

Methodes d'utilisation de lp8, une proteine liee au pdgf, afin de traiter les troubles musculosquelettiques Download PDF

Info

Publication number
WO2001032197A3
WO2001032197A3 PCT/US2000/026272 US0026272W WO0132197A3 WO 2001032197 A3 WO2001032197 A3 WO 2001032197A3 US 0026272 W US0026272 W US 0026272W WO 0132197 A3 WO0132197 A3 WO 0132197A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
pdgf
related protein
musculoskeletal disorders
treat musculoskeletal
Prior art date
Application number
PCT/US2000/026272
Other languages
English (en)
Other versions
WO2001032197A2 (fr
Inventor
Janet Mary Hock
Songqing Na
Lisa Janine Hammond
Alexei Kharitonenkov
Venkatesh Krishnan
Gerald Wayne Becker
Original Assignee
Lilly Co Eli
Janet Mary Hock
Songqing Na
Lisa Janine Hammond
Alexei Kharitonenkov
Venkatesh Krishnan
Gerald Wayne Becker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Janet Mary Hock, Songqing Na, Lisa Janine Hammond, Alexei Kharitonenkov, Venkatesh Krishnan, Gerald Wayne Becker filed Critical Lilly Co Eli
Priority to AU14306/01A priority Critical patent/AU1430601A/en
Publication of WO2001032197A2 publication Critical patent/WO2001032197A2/fr
Publication of WO2001032197A3 publication Critical patent/WO2001032197A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]

Abstract

L'invention concerne des compositions et des méthodes permettant de traiter l'ostéopénie, l'ostéoporose, l'arthrite, la sarcopénie, les maladies périodontiques ou de stimuler la croissance osseuse. Ces méthodes consistent à administrer une quantité thérapeutiquement efficace de LP8, un fragment de LP8, un analogue de LP8 et/ou un antagoniste ou un agoniste de LP8.
PCT/US2000/026272 1999-11-02 2000-10-24 Methodes d'utilisation de lp8, une proteine liee au pdgf, afin de traiter les troubles musculosquelettiques WO2001032197A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14306/01A AU1430601A (en) 1999-11-02 2000-10-24 Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16320399P 1999-11-02 1999-11-02
US16305699P 1999-11-02 1999-11-02
US16320499P 1999-11-02 1999-11-02
US60/163,204 1999-11-02
US60/163,056 1999-11-02
US60/163,203 1999-11-02

Publications (2)

Publication Number Publication Date
WO2001032197A2 WO2001032197A2 (fr) 2001-05-10
WO2001032197A3 true WO2001032197A3 (fr) 2002-03-07

Family

ID=27388828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026272 WO2001032197A2 (fr) 1999-11-02 2000-10-24 Methodes d'utilisation de lp8, une proteine liee au pdgf, afin de traiter les troubles musculosquelettiques

Country Status (2)

Country Link
AU (1) AU1430601A (fr)
WO (1) WO2001032197A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8870954B2 (en) 2008-09-09 2014-10-28 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US9545377B2 (en) 2004-10-14 2017-01-17 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods of use thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6663870B2 (en) 1998-12-07 2003-12-16 Zymogenetics, Inc. Methods for promoting growth of bone using zvegf3
WO2007092622A2 (fr) 2006-02-09 2007-08-16 Biomimetic Therapeutics, Inc. Compositions et méthodes pour le traitement d'os
ES2664229T3 (es) 2006-06-30 2018-04-18 Biomimetic Therapeutics, Llc Composiciones y métodos de biomatriz-PDGF para el tratamiento de lesiones del manguito rotador
WO2011103598A1 (fr) 2010-02-22 2011-08-25 Biomimetic Therapeutics, Inc. Compositions de facteur de croissance dérivé des plaquettes et procédés pour le traitement de tendinopathies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376636A (en) * 1991-03-12 1994-12-27 Creative Biomolecules, Inc. Method for promoting tissue repair and regeneration using PDGF and glucocorticoids
WO1995028950A1 (fr) * 1994-04-20 1995-11-02 Institute Of Molecular Biology, Inc. Administration de facteur de croissance derive de plaquettes et de medicaments osteotropes pour l'osteoporose et la regeneration osseuse
US5533836A (en) * 1993-03-29 1996-07-09 Zymogenetics, Inc. Compositions and methods for stimulating the growth of osteoblasts
WO1999047677A2 (fr) * 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologues de vegf et bmp1
WO2000037641A2 (fr) * 1998-12-22 2000-06-29 Janssen Pharmaceutica N.V. Facteur de croissance endotheliale vasculaire- x
WO2000059940A2 (fr) * 1999-04-06 2000-10-12 Eli Lilly And Company Gene et proteine lies au facteur de croissance d'origine plaquettaire

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376636A (en) * 1991-03-12 1994-12-27 Creative Biomolecules, Inc. Method for promoting tissue repair and regeneration using PDGF and glucocorticoids
US5533836A (en) * 1993-03-29 1996-07-09 Zymogenetics, Inc. Compositions and methods for stimulating the growth of osteoblasts
WO1995028950A1 (fr) * 1994-04-20 1995-11-02 Institute Of Molecular Biology, Inc. Administration de facteur de croissance derive de plaquettes et de medicaments osteotropes pour l'osteoporose et la regeneration osseuse
WO1999047677A2 (fr) * 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologues de vegf et bmp1
WO2000037641A2 (fr) * 1998-12-22 2000-06-29 Janssen Pharmaceutica N.V. Facteur de croissance endotheliale vasculaire- x
WO2000059940A2 (fr) * 1999-04-06 2000-10-12 Eli Lilly And Company Gene et proteine lies au facteur de croissance d'origine plaquettaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAMADA T ET AL: "A NOVEL GENE DERIVED FROM DEVELOPING SPINAL CORDS, SCDGF, IS A UNIQUE MEMBER OF THE PDGF/VEGF FAMILY", FEBS LETTERS,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM,NL, vol. 475, no. 2, 2000, pages 97 - 102, XP000952876, ISSN: 0014-5793 *
LI X ET AL: "PDGF-C IS A NEW PROTEASE-ACTIVATED LIGAND FOR THE PDGF ALPHA-RECEPTOR", NATURE CELL BIOLOGY,MACMILLAN PUBLISHERS,GB, vol. 2, no. 5, May 2000 (2000-05-01), pages 302 - 309, XP000956444, ISSN: 1465-7392 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9545377B2 (en) 2004-10-14 2017-01-17 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods of use thereof
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US8870954B2 (en) 2008-09-09 2014-10-28 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries

Also Published As

Publication number Publication date
AU1430601A (en) 2001-05-14
WO2001032197A2 (fr) 2001-05-10

Similar Documents

Publication Publication Date Title
HK1066534A1 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
FR06C0032I2 (fr) Formulations proteiniques
WO2001043732A3 (fr) Utilisation d'antagonistes des recepteurs de retinoides dans le traitement de maladies cartilagineuses et osseuses
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
HK1078466A1 (en) Treatment of affective disorders by the combined action of a nicotinic ; receptor agonist and a monoaminergic substance
HUP0401210A3 (en) Use of nk-1 receptor antagonists for the preparation of pharmaceutical compositions treating of brain, spinal or nerve injury
WO2004016256A3 (fr) Agonisme du recepteur 5ht2a pour le traitement du dysfonctionnement de la thermoregulation
MY121054A (en) Calcilytic compounds as calcium receptor antagonists.
WO2007006732A8 (fr) Combinaison synergique pour traiter une douleur (agoniste du recepteur canabinoide et agoniste du recepteur opioide)
WO2001032197A3 (fr) Methodes d'utilisation de lp8, une proteine liee au pdgf, afin de traiter les troubles musculosquelettiques
WO2001080894A3 (fr) Utilisation d'antagonistes ou d'agonistes du recepteur retinoide dans le traitement de pathologies des cartilages et os
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
MY130725A (en) Composition and method for treating allergic diseases
AU2003264297A1 (en) Use of vanilloid receptor antagonists for the treatment of pain
DE60006948T2 (de) Antagonismus des estrogen-rezeptors-beta und knochenkrankheiten
WO2001089450A3 (fr) Traitement de pathologies musculosquelettiques par le polypeptide lp85 et des analogues de celui-ci
EP1400810A3 (fr) Récepteurs des oestrogènes et les maladies de l'os
IL152668A0 (en) Pharmaceutical compositions comprising vip-related peptides for the treatment of sexual disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP